Amylin vs GLP-1: CagriSema and Emerging Obesity Drugs

Amylin and GLP-1 are different hormones and drug targets. Their effects can overlap in appetite and metabolic research, but an amylin analogue is not automatically a GLP-1 receptor agonist. CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 analogue. Petrelintide and eloralintide belong to the amylin research landscape rather than being new names for semaglutide.

That distinction matters when a headline calls every emerging obesity medicine “the next GLP-1”. It can erase the molecule actually tested, hide a combination’s components and encourage comparisons between trials that asked different questions.

Sources checked: 25 October 2026. This guide explains mechanisms and selected published human studies. The study table is not a current regulatory register, a treatment ranking or a guide to using investigational products.

Amylin versus GLP-1: a mechanism map

The FDA’s 2014 pramlintide label describes the underlying amylin physiology, including its pancreatic origin and relationship to insulin secretion. It is cited here for that mechanism description, not as current prescribing advice or an approval for newer obesity compounds.

For the corresponding hormone-versus-medicine distinction on the other side of the table, see what GLP-1 means. Mechanisms help classify the intervention. Clinical trials are still needed to establish outcomes in a defined population.

Cagrilintide, CagriSema, petrelintide and eloralintide: decode the names

Cagrilintide

A long-acting amylin analogue studied alone and in combinations. Its monotherapy evidence is distinct from combination evidence.

CagriSema

The cagrilintide–semaglutide combination. It contains two active components; it is not another spelling of cagrilintide alone.

Petrelintide

A human amylin analogue studied in the ZUPREME programme. A published study and a newly registered programme are different evidence events.

Eloralintide

Described in its phase 2 publication as a selective amylin receptor agonist. Results for it do not establish results for every amylin-targeting candidate.

Use the full intervention name when reading a result. “Amylin drug” identifies a research family; it does not identify the exact molecule, formulation, comparator or regulatory indication.

Human-study ledger: what has actually been published?

These are selected primary publications, not an exhaustive pipeline. The phase below describes the cited study, not necessarily the most advanced programme running today. A later phase does not erase the limitations of an earlier study or create a completed result for a different trial.

For example, REDEFINE 1 reported an estimated mean body-weight change of −20.4% with the combination and −3.0% with placebo at 68 weeks using its treatment-policy estimand. Those figures belong to that specific analysis. They are not a measured effect for cagrilintide alone, and a placebo comparison is not a direct comparison with petrelintide or eloralintide.

The named trials also assess adverse events. Gastrointestinal events appear in the cagrilintide and CagriSema publications, so a mechanism-based claim that an entire family is free of these effects would exceed the evidence. Different receptor targets do not remove the need to read each trial’s safety findings.

Does targeting two pathways prove synergy?

No. Showing that a combination changes an endpoint does not automatically establish a particular interaction mechanism, explain which component caused each effect or prove that any two substances with similar labels can be combined.

REDEFINE 1 is especially useful because it includes individual-component groups as well as the combination and placebo. Readers can inspect the actual comparisons rather than assuming that all of the combination’s result belongs to one component. Even that design does not justify extrapolating to a different formulation or an unstudied pairing.

Questions about a diabetes-specific CagriSema trial belong to the study and population actually tested. Our REIMAGINE 2 analysis keeps that evidence separate from REDEFINE 1.

Why the biggest weight-loss number is not a fair league table

Before comparing percentages, align five fields: population, comparator, duration, endpoint and estimand. A sixth useful field is discontinuation: who stopped the intervention, who remained under follow-up and how missing observations were handled?

A trial in people without diabetes can answer a different question from one in people with type 2 diabetes. A 26-week phase 2 study is not equivalent to a 68-week phase 3 study. An analysis assuming continued adherence is not identical to one following the intended assignment despite treatment changes.

These are limits on interpretation, not reasons to ignore promising findings. They let a reader recognise a meaningful signal without turning it into a treatment ranking. See the trial-reading guide for a more detailed endpoint and missing-data checklist.

Three statuses to keep separate

1. Registered: a study record describes a planned or ongoing investigation.
2. Results available: a specific trial has posted results, reported a topline finding or published a paper. Those formats offer different levels of detail.
3. Regulator decision: a regulator has assessed a particular product and indication in its jurisdiction.

None of these statuses should stand in for the other two. This article’s ledger identifies published studies; it does not claim that all named candidates are approved, unapproved everywhere or available in Australia. Follow the obesity-trial results tracker for programme updates and the Australian status guide for local decisions.

Follow the molecule, then the evidence

To interpret the next amylin headline, identify whether it concerns a natural hormone, one drug candidate, a combination or an entire programme. Open the primary study, keep its population and analysis attached to the finding, and check whether a separate regulatory claim is actually sourced.

The same naming discipline applies to pills: our oral GLP-1 approval and trial tracker separates oral semaglutide from the nonpeptide molecule orforglipron. Route, chemistry, receptor action and clinical result are related facts, not synonyms.

Source scope: the mechanism source and four study records linked above support this selected explainer. Original publication years are retained. The 25 October check is an editorial source check, not a new clinical review by a named health professional.

Educational research information. No personal medical advice, drug-combination recommendation, administration instructions or sourcing guidance.